[{"orgOrder":0,"company":"Edith Wolfson Medical Center","sponsor":"Orgenesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Edith Wolfson Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Edith Wolfson Medical Center \/ Orgenesis","highestDevelopmentStatusID":"1","companyTruncated":"Edith Wolfson Medical Center \/ Orgenesis"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Mabxience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"PD-1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Teva Pharmaceutical Industries \/ Mabxience","highestDevelopmentStatusID":"1","companyTruncated":"Teva Pharmaceutical Industries \/ Mabxience"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Univo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Univo Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Can-Fite BioPharma \/ Univo Pharmaceuticals"},{"orgOrder":0,"company":"Purple Biotech","sponsor":"Menashe Bar-Eli","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"NT219","moa":"||IRS1\/IRS2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Purple Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Purple Biotech \/ Menashe Bar-Eli","highestDevelopmentStatusID":"1","companyTruncated":"Purple Biotech \/ Menashe Bar-Eli"},{"orgOrder":0,"company":"Isotopia","sponsor":"CPDC Centre for Probe Development and Commercialization","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"n.c.a. 177-Lu","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Isotopia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotopia \/ CPDC Centre for Probe Development and Commercialization","highestDevelopmentStatusID":"1","companyTruncated":"Isotopia \/ CPDC Centre for Probe Development and Commercialization"},{"orgOrder":0,"company":"Isotopia","sponsor":"Seibersdorf Labor GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"n.c.a. 177-Lu","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Isotopia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotopia \/ Seibersdorf Labor GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Isotopia \/ Seibersdorf Labor GmbH"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CM-24","moa":"||CEACAM1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kitov Pharma \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Kitov Pharma \/ Bristol Myers Squibb"}]

Find Novel Oncology Drugs in Clinical Development in ISRAEL

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : mAbxience will lead the development and production of an anti PD-1 biosimilar and Teva will manage regulatory approvals and oversee commercialization of this oncology treatment.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 10, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Mabxience

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Lead Product(s) : n.c.a. 177-Lu

                          Therapeutic Area : Oncology

                          Study Phase : Undisclosed

                          Sponsor : CPDC Centre for Probe Development and Commercialization

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : 177Lu n.c.a (No-carrier-added Lutetium-177) is a very versatile isotope, and worldwide numerous clinical trials are being held, studying the effects of this isotope, used radiometal for targeted radiotherapy.

                          Product Name : n.c.a. 177-Lu

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 06, 2022

                          Lead Product(s) : n.c.a. 177-Lu

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : CPDC Centre for Probe Development and Commercialization

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : This collaboration will evaluate the potential efficacy of the combination of NT219, a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3, and immuno-oncology drugs, such as anti-CTLA4 or anti-PD1/PDL1 antibodies.

                          Product Name : NT219

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 26, 2021

                          Lead Product(s) : NT219,Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Menashe Bar-Eli

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Seibersdorf Labor, a GMP Contract manufacturing of radiopharmaceuticals, a global leader in the development, production, and commercialization of radiopharmaceuticals, will produce 177Lu n.c.a in collaboration with Isotopia Molecular Imaging for distribu...

                          Product Name : n.c.a. 177-Lu

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 18, 2021

                          Lead Product(s) : n.c.a. 177-Lu

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Seibersdorf Labor GmbH

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The Phase 1/2 clinical trial will evaluate CM24, a monoclonal antibody targeting CEACAM1, in combination with nivolumab (Opdivo®) in patients with advanced non-small cell lung cancer.

                          Product Name : CM-24

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 11, 2020

                          Lead Product(s) : CM-24,Paclitaxel,Nivolumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Bristol Myers Squibb

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Namodenoson may create powerful combination treatment with checkpoint inhibitors.

                          Product Name : CF102

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 24, 2020

                          Lead Product(s) : Namodenoson,Nivolumab,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : China Patent titled "Anti-TIGIT Antibodies, Anti-PVRIG Antibodies and Combinations Thereof," relates to the composition of matter of COM902, alone or in combination with a second antibody targeting an immune checkpoint, including PD-1 and PVRIG.

                          Product Name : COM902

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 11, 2020

                          Lead Product(s) : COM902,COM701,Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Findings suggest use of cannabinoid-based drugs to treat diseases in which there is an overexpression of A3AR including cancer, autoimmune, inflammatory and metabolic diseases.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          January 16, 2020

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Univo Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Clinical study will be undertaken with goal of utilizing and validating a number of Orgenesis’ proprietary POCare Technologies, including an automated cell culturing system for the generation and expansion tumor infiltrating lymphocytes for use in adop...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          January 06, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Orgenesis

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank